CPC A61K 47/60 (2017.08) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] | 22 Claims |
1. A polyethylene glycol conjugated drug of formula (I) or a pharmaceutically acceptable salt thereof,
wherein:
M is —C(═O)—C1-6 alkylene-C(═O)—, —C(═O)—, —NH—C1-6alkylene-NH—, —C(═O)—C1-6 alkylene-NH—,
or PEGm; wherein, PEGm is a single-arm or multi-arm polyethylene glycol segment, and its number-average molecular weight is 5k-40k;
A1, A1′ each independently are
A2 independently is a direct bond or
L1 independently is a direct bond or —C(═O)—C1-6 alkylene-C(═O)—;
W1, W1′, W2 each independently are Q1,
Z4, Z3, Z2, Z1, Z0 each independently are
Q is —N-AC;
Q1 is —N1-AC1;
Q2 is —N2-AC2;
N, N1, N2 each independently are GFLG, G,
AC, AC1, AC2 each independently are drug molecules;
n1, n2 each independently are 0, 1, 2, 3, 4, 5 or 6;
Y, Y′ each independently are a direct bond, GLFG, —C(═O)—C1-6 alkylene-C(═O)—,
X, X′ each independently are
PEG is a single-arm polyethylene glycol segment, and its number-average molecular weight independently is 5k-40k;
j1 is 1, 2, 3, 4, 5 or 6;
j2, j3 each independently are 0 or 1.
|